Provepharm Sas Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PROVEPHARM SAS
PROVEPHARM SAS has four approved drugs.
There are three US patents protecting PROVEPHARM SAS drugs. There is one tentative approval on PROVEPHARM SAS drugs.
Summary for Provepharm Sas
| US Patents: | 3 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Provepharm Sas
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provepharm Sas | ZYOGREEN | indocyanine green | SOLUTION;INTRAVENOUS, INTERSTITIAL | 218579-001 | Jul 10, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | 11,845,867 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | 11,499,050 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | 10,927,258 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Provepharm Sas | PROVAYBLUE | methylene blue | SOLUTION;INTRAVENOUS | 204630-002 | Jul 18, 2019 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Provepharm Sas | BLUDIGO | indigotindisulfonate sodium | SOLUTION;INTRAVENOUS | 216264-001 | Jul 8, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Provepharm Sas Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3559121 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2018116325 | ⤷ Start Trial |
| European Patent Office | 3559121 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Provepharm Sas Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0164843 | SPC/GB98/028 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: 153 SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONIC ACID (QUADRAMET); REGISTERED: CH CH 54265 19971006; UK EU/1/97/057/001 19980205 |
| 0481754 | SPC/GB06/032 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ENTECAVIR-(2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE CYCLOPENTYL)-6H-PURIN-6-ONE AND HYDRATES THEREOF, PARTICULARLY THE MONOHYDRATE; REGISTERED: UK EU/1/06/343/001 20060626; UK EU/1/06/343/002 20060626; UK EU/1/06/343/003 20060626; UK EU/1/06/343/004 20060626; UK EU/1/06/343/005 20060626 |
| 0260415 | SPC/GB01/013 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-UREA (CARMUSTINE) COMBINED WITH A POLYANHYDRIDE HAVING A WEIGHT AVERAGE MOLECULAR WEIGHT OF GREATER THAN 20,000 PREPARED BY THE POLYCONDENSATION OF: (I) 4,4'-(TRIMETHYLENEDIOXY)-DIBENZOIC ACID; AND (II) SEBACIC ACID (POLI; REGISTERED: FR 561 907-5 19990105; UK PL 00012/0337 20000928 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
